Medical Oncology

, 36:64 | Cite as

The role of radiotherapy in epithelial ovarian cancer: a literature overview

  • Giuseppe Carlo Iorio
  • Stefania Martini
  • Francesca Arcadipane
  • Umberto Ricardi
  • Pierfrancesco FrancoEmail author
Review Article


Ovarian cancer (OC) accounts for 3% of all cancer in women and for 5% of all cancer-related deaths. Epithelial Ovarian Cancer (EOC) is a radiosensitive malignancy with a poor prognosis. In the pre-chemotherapy era, radiation therapy (RT) delivered to the abdominopelvic region (whole abdominal irradiation, WAI) has historically played a role in the adjuvant and consolidation setting. Specific cluster of patients with early-stage disease and definite histologies may take advantage of RT. Platinum-based chemotherapy (CT) has replaced RT and plays a major role in most of the clinical settings. Radiation Therapy for palliation is recommended in patients with localized symptoms. Nevertheless, modern RT represents a reliable treatment option, with a mild toxicity profile, particularly effective for oligo-recurrent or progressive disease. The present literature review aims to highlight the historical role of RT in EOC, the actual lines of evidence, and the future perspectives.


Epithelial ovarian cancer Radiotherapy Radiation Stereotactic ablative radiotherapy 




Compliance with ethical standards

Conflict of interest

We declare that we do not have any conflict of interest.

Ethical approval

The present study has been reviewed and approved by the Internal Review Board of the Department of Oncology of the University of Turin at AOU Citta’ della Salute e della Scienza, Turin, Italy.

Research involving human and animal participants

No human participants were involved in the present study.


  1. 1.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.CrossRefGoogle Scholar
  3. 3.
    Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia? Lancet. 1971;2:163.CrossRefGoogle Scholar
  4. 4.
    Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90:1774–86.CrossRefGoogle Scholar
  5. 5.
    Zeppernick F, Meinhold-Heerlein I. The new FIGO staging system for ovarian, fallopian tube, and primary peritoneal cancer. Arch Gynecol Obstet. 2014;290:839–42.CrossRefGoogle Scholar
  6. 6.
    Choi M, Fuller CD, Thomas CR Jr, Wang SJ. Conditional survival in ovarian cancer: results from the SEER dataset 1988-2001. Gynecol Oncol. 2008;109:203–9.CrossRefGoogle Scholar
  7. 7.
    Harlan LC, Clegg LX, Trimble EL. Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the United States. J Clin Oncol. 2003;21:3488–94.CrossRefGoogle Scholar
  8. 8.
    Albuquerque K, Patel M, Liotta M, Harkenrider M, Guo R, Small W Jr, et al. Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer. Int J Gynecol Cancer. 2016;26:655–60.CrossRefGoogle Scholar
  9. 9.
    Chang JS, Koom WS, Kim SW, Kim S, Kim YB, Kim GE. Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy. J Gynecol Oncol. 2013;24:146–53.CrossRefGoogle Scholar
  10. 10.
    Brown AP, Jhingran A, Klopp AH, Schmeler KM, Ramirez PT, Eifel PJ. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol. 2013;130:300–5.CrossRefGoogle Scholar
  11. 11.
    De Felice F, Marchetti C, Di Mino A, Palaia I, Benevento I, Musella A, et al. Recurrent ovarian cancer: the role of radiation therapy. Int J Gynecol Cancer. 2017;27:690–5.CrossRefGoogle Scholar
  12. 12.
    Ricardi U, Filippi AR, Franco P. New concepts and insights into the role of radiation therapy in extracranial metastastic disease. Expert Rev Anticancer Ther. 2013;13:1145–55.CrossRefGoogle Scholar
  13. 13.
    Fields EC, McGuire WP, Lin L, Temkin SM. Radiation treatment in women with ovarian cancer: past, Present, and future. Front Oncol. 2017;7:177.CrossRefGoogle Scholar
  14. 14.
    Winter-Roach BA, Kitchener HC, Dickinson HO. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochr Database Syst Rev. 2009. Scholar
  15. 15.
    Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi24–32.CrossRefGoogle Scholar
  16. 16.
    Pezner RD, Stevens KR Jr, Tong D, Allen CV. Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloids. Cancer. 1978;42:2563–71.CrossRefGoogle Scholar
  17. 17.
    Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerualth A, et al. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report. J Clin Oncol. 1988;6:1254–63.CrossRefGoogle Scholar
  18. 18.
    Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon J, et al. Ovarian carcinoma: improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol. 1979;134:793–800.CrossRefGoogle Scholar
  19. 19.
    Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr. 1975;42:149–53.PubMedGoogle Scholar
  20. 20.
    Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD, et al. The role of adjuvant therapy in stage I ovarian cancer. Am J Obstet Gynecol. 1980;138:139–45.CrossRefGoogle Scholar
  21. 21.
    Nagai Y, Inamine M, Hirakawa M, Kamiyama K, Ogawa K, Toita T, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:469–73.CrossRefGoogle Scholar
  22. 22.
    Dinniwell R, Lock M, Pintilie M, Fyles A, Laframboise S, Depetrillo D, et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int J Radiat Oncol Biol Phys. 2005;62:104–10.CrossRefGoogle Scholar
  23. 23.
    Swenerton KD, Santos JL, Gilks CB, Kobel M, Hoskins PJ, Wong F, et al. Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann Oncol. 2011;22:341–7.CrossRefGoogle Scholar
  24. 24.
    Hoskins PJ, Le N, Gilks B, Tinker A, Santos J, Wong F, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30:1656–62.CrossRefGoogle Scholar
  25. 25.
    Bruzzone M, Repetto L, Chiara S, Campora E, Conte PF, Orsatti M, et al. Chemotherapy versus radiotherapy in the management of ovarian cancer patients with pathological complete response or minimal residual disease at second look. Gynecol Oncol. 1990;38:392–5.CrossRefGoogle Scholar
  26. 26.
    Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE. A randomized trial comparing single-agent carboplatin with carboplatin followed by radiotherapy for advanced ovarian cancer: a North Thames Ovary Group study. J Clin Oncol. 1993;11:440–8.CrossRefGoogle Scholar
  27. 27.
    Thomas GM. Is there a role for consolidation or salvage radiotherapy after chemotherapy in advanced epithelial ovarian cancer? Gynecol Oncol. 1993;51:97–103.CrossRefGoogle Scholar
  28. 28.
    Pickel H, Lahousen M, Petru E, Stettner H, Hackl A, Kapp K, et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol Oncol. 1999;72:215–9.CrossRefGoogle Scholar
  29. 29.
    Sorbe B. Swedish-Norgewian Ovarian Cancer Study G: consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer. 2003;13:278–86.CrossRefGoogle Scholar
  30. 30.
    Varia MA, Stehman FB, Bundy BN, Benda JA, Clarke-Pearson DL, Alvarez RD, et al. Intra- peritoneal radioactive phosphorus (32P) versus observation after negative second-look laparotomy for stage III ovarian carcinoma: a randomized trial of the Gynecologic Oncology Group. J Clin Oncol. 2003;21:2849–55.CrossRefGoogle Scholar
  31. 31.
    Thomas GM, Dembo AJ. Integrating radiation therapy into the management of ovarian cancer. Cancer. 1993;71:1710–8.CrossRefGoogle Scholar
  32. 32.
    Rochet N, Lindel K, Katayama S, Schubert K, Herfarth K, Schneeweiss A, et al. Intensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer: four-year outcomes. Strahlenther Onkol. 2015;191:582–9.CrossRefGoogle Scholar
  33. 33.
    Arians N, Kieser M, Benner L, Rochet N, Katayama S, Sterzing F, et al. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III): first results of a prospective phase 2 study. Int J Radiat Oncol Biol Phys. 2017;99:912–20.CrossRefGoogle Scholar
  34. 34.
    Hong L, Alektiar K, Chui C, LoSasso T, Hunt M, Spirou S, et al. IMRT of large fields: whole-abdomen irradiation. Int J Radiat Oncol Biol Phys. 2002;54:278–89.CrossRefGoogle Scholar
  35. 35.
    Swamidas VJ, Mahantshetty U, Vineeta G, Engineer R, Deshpande DD, Sarin R, et al. Treatment planning of epithelial ovarian cancers using helical tomotherapy. J Appl Clin Med Phys. 2009;10:3003.PubMedGoogle Scholar
  36. 36.
    Sedlacek TV, Spyropoulus P, Cifaldi R, Glassburn J, Fisher S. Whole-abdomen radiation therapy as salvage treatment for epithelial ovarian carcinoma. Cancer J Sci Am. 1997;3:358–63.PubMedGoogle Scholar
  37. 37.
    Haddock MG, Petersen IA, Webb MJ, Wilson TO, Podratz KC, Gunderson LL. IORT for locally advanced gynecological malignancies. Front Radiat Ther Oncol. 1997;31:256–9.CrossRefGoogle Scholar
  38. 38.
    Yap OWS, Kapp DS, Teng NNH, Husain H. Intraoperative radiation therapy in recurrent ovarian cancer. Int J Radiat Oncol Biol Phys. 2005;63:1114–21.CrossRefGoogle Scholar
  39. 39.
    Franco P, De Bari B, Ciammella P, Fiorentino A, Chiesa S, Amelio D, et al. The role of stereotactic ablative radiotherapy in oncological and non-oncological clinical settings: highlights from the 7th Meeting of AIRO – Young Members Working Group (AIRO Giovani). Tumori. 2014;100:e214–9.CrossRefGoogle Scholar
  40. 40.
    Lazzari R, Ronchi S, Gandini S, Surgo A, Volpe S, Piperno G, et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int J Radiation Oncol Biol Phys. 2018;101:650–60.CrossRefGoogle Scholar
  41. 41.
    Kunos C, Brindle JM, Debernardo R. Stereotactic radiosurgery for gynecologic cancer. J Vis Exp. 2012;62:3793.Google Scholar
  42. 42.
    Stereotactic body radiation therapy in treating patients with recurrent primary ovarian or uterine cancer. Identifier (NCT number): NCT03325634.Google Scholar
  43. 43.
    Corn BW, Lanciano RM, Boente M, Hunter WM, Ladazack J, Ozols RF. Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer. 1994;74:2979–83.CrossRefGoogle Scholar
  44. 44.
    Gelblum D, Mychalczak B, Almadrones L, Spriggs D, Barakat R. Palliative benefit of external-beam radiation in the management of platinum refractory epithelial ovarian carcinoma. Gynecol Oncol. 1998;69:36–41.CrossRefGoogle Scholar
  45. 45.
    Adelson MD, Wharton JT, Delclos L, Copeland L, Gershenson D. Palliative radiotherapy for ovarian cancer. Int J Radiat Oncol Biol Phys. 1987;13:17–21.CrossRefGoogle Scholar
  46. 46.
    Fyles AW, Dembo AJ, Bush RS, Levin W, Manchul LA, Pringle JF. Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma. Int J Radiat Oncol Biol Phys. 1992;22:847–51.CrossRefGoogle Scholar
  47. 47.
    Nauman RW, Coleman RL, Brown J, Moore KN. Phase III trials in ovarian cancer: The evolving landscape of front line therapy. Gynecol Oncol. 2019;153(2):436–44.CrossRefGoogle Scholar
  48. 48.
    Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27:i40–4.CrossRefGoogle Scholar
  49. 49.
    Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852–61.CrossRefGoogle Scholar
  50. 50.
    Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8:69105–24.CrossRefGoogle Scholar
  51. 51.
    Filippi AR, Franco P, Ricardi U. Is clinical radiosensitivity a complex genetically controlled event? Tumori. 2006;92:87–91.PubMedGoogle Scholar
  52. 52.
    PDL-1 inhibition and focal sensitizing radiotherapy in recurrent ovarian/primary peritoneal/fallopian tube cancers. Identifier (NCT Number): NCT03283943.Google Scholar
  53. 53.
    Durvalumab, Tremelimumab + Radiotherapy in gynecologic cancer. Identifier (NCT Number): NCT03277482.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Oncology, Radiation Oncology, School of MedicineUniversity of TurinTurinItaly
  2. 2.Department of Oncology, Radiation OncologyAOU Citta’ della Salute e della ScienzaTurinItaly

Personalised recommendations